Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors

Maekawa, Naoya; Konnai, Satoru; Asano, Yumie; Otsuka, Takumi; Aoki, Eri; Takeuchi, Hiroto; Kato, Yukinari; Kaneko, Mika K.; Yamada, Shinji; Kagawa, Yumiko; Nishimura, Maki; Takagi, Satoshi; Deguchi, Tatsuya; Ohta, Hiroshi; Nakagawa, Takayuki; Suzuki, Yasuhiko; Okagawa, Tomohiro; Murata, Shiro; Ohashi, Kazuhiko

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors

Maekawa, Naoya; Konnai, Satoru; Asano, Yumie et al.

PLoS ONE, 2023, 18(1), e0281143

Permalink : https://hdl.handle.net/2115/89157

このアイテムのアクセス数:593件（2026-08-19 00:39 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1371/journal.pone.0281143			17

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/89157
タイトル	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
著者	Maekawa, Naoya ; Konnai, Satoru ; Asano, Yumie ; Otsuka, Takumi ; Aoki, Eri ; Takeuchi, Hiroto ; Kato, Yukinari ; Kaneko, Mika K. ; Yamada, Shinji ; Kagawa, Yumiko ; Nishimura, Maki ; Takagi, Satoshi ; Deguchi, Tatsuya ; Ohta, Hiroshi ; Nakagawa, Takayuki ; Suzuki, Yasuhiko ; Okagawa, Tomohiro ; Murata, Shiro ; Ohashi, Kazuhiko
e-Rad_Researcher 70829035 著者名 Maekawa, Naoya
e-Rad_Researcher 40396304 著者名 Konnai, Satoru
著者名 Asano, Yumie
著者名 Otsuka, Takumi
著者名 Aoki, Eri
著者名 Takeuchi, Hiroto
著者名 Kato, Yukinari
著者名 Kaneko, Mika K.
著者名 Yamada, Shinji
著者名 Kagawa, Yumiko
著者名 Nishimura, Maki
著者名 Takagi, Satoshi
著者名 Deguchi, Tatsuya
著者名 Ohta, Hiroshi
著者名 Nakagawa, Takayuki
e-Rad_Researcher 90206540 著者名 Suzuki, Yasuhiko
e-Rad_Researcher 80829036 著者名 Okagawa, Tomohiro
e-Rad_Researcher 10579163 著者名 Murata, Shiro
e-Rad_Researcher 90250498 著者名 Ohashi, Kazuhiko
言語	英語
発行日	2023-01-26
出版者	PLOS
収録物名	PLoS ONE
巻(号)	18(1)
ページ	e0281143
抄録	Spontaneous tumors are a major cause of death in cats. Treatment of human tumors has progressed dramatically in the past decade, partly due to the success of immunotherapies using immune checkpoint inhibitors, such as anti-programmed death 1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies. However, little is known about the PD-1 pathway and its association with tumor disease in cats. This study investigated the applicability of anti-PD-1/PD-L1 therapy in feline tumors. We first determined the complete coding sequence of feline PD-L1 and PD-L2, and found that the deduced amino acid sequences of feline PD-L1/PD-L2 share high sequence identities (66-83%) with orthologs in other mammalian species. We prepared recombinant feline PD-1, PD-L1, and PD-L2 proteins and confirmed receptor-ligand binding between PD-1 and PD-L1/PD-L2 using flow cytometry. Next, we established an anti-feline PD-L1 monoclonal antibody (clone CL1Mab-7) to analyze the expression of PD-L1. Flow cytometry using CL1Mab-7 revealed the cell surface expression of PD-L1 in a feline macrophage (Fcwf-4) and five mammary adenocarcinoma cell lines (FKNp, FMCm, FYMp, FONp, and FONm), and showed that PD-L1 expression was upregulated by interferon-gamma stimulation. Finally, immunohistochemistry using CL1Mab-7 also showed PD-L1 expression in feline squamous cell carcinoma (5/5, 100%), mammary adenocarcinoma (4/5, 80%), fibrosarcoma (5/5, 100%), and renal cell carcinoma (2/2, 100%) tissues. Our results strongly encourage further investigations of the PD-1/PD-L1 pathway as a potential therapeutic target for feline tumors.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1932-6203
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1371/journal.pone.0281143